Site Editor
Joyce F. Liu, MD, MPH
Joyce F. Liu, MD, MPH
Posted: Tuesday, January 21, 2025
In an article published in Cancers, researchers examined the use of intraperitoneal (IP) chemotherapy with and without bevacizumab vs intravenous (IV) chemotherapy with bevacizumab in the front-line adjuvant treatment of patients with advanced ovarian cancer. Sheng-Mou Hsiao, MD, of the National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, and colleagues reported that IP chemotherapy without bevacizumab yielded better progression-free survival than IV chemotherapy with bevacizumab.
“In our study, the use of IP without bevacizumab was associated with a better progression-free survival and overall survival when compared with IV with bevacizumab. The adjusted hazard ratio of the IP was 0.45 in progression-free survival compared to IV with bevacizumab,” stated the investigators.
Medical records from a total of 143 women with stage II to IV cancer were included in this study. Patients were separated into three groups. The IP group (n = 57) was treated with front-line adjuvant IP cisplatin/paclitaxel without bevacizumab, the IV group (n = 63) was treated with IV carboplatin/paclitaxel without bevacizumab, and the IVB group (n = 23) was treated with IV carboplatin/paclitaxel with bevacizumab.
Findings revealed that the IP group without bevacizumab had better progression-free survival compared with the IV group (49.1 months, 95% confidence interval [CI] = 27.8 months to infinity vs 11.9 months, 95% CI = 11.2–16.2 months). The IP group without bevacizumab also yielded higher overall survival than did the IV group (not reached, 95% CI = 55.6 months to infinity vs 38.9 months, 95% CI = 21.9 months to infinity; adjusted hazard ratio = 0.34, 95% CI = 0.15–0.79, P = .012).
Disclosure: The study authors reported no conflicts of interest.
